FDA Panel Backs Cholesterol Drug but Raises Concerns

An FDA advisory panel backed the cholesterol-lowering drug Praluent, but panelists said the drug should be limited to certain high-risk groups.

from WSJ.com: US Business http://ift.tt/1B4X1Mg
via IFTTT